Breast cancer liver metastases: US-guided percutaneous radiofrequency ablation - Intermediate and long-term survival rates

Radiology

Volumn 253, Issue 3, 2009, Pages 861-869

  Meloni, Maria Franca ^a   Andreano, Anita ^b   Laeseke, Paul F ^c,d   Livraghi, Tito ^a   Sironi, Sandro ^b   Lee Jr , Fred T ^c  

^a DESIO HOSPITAL   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d University of Wisconsin Madison   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IOPAMIDOL; SONOVUE; CONTRAST AGENT BR1; CONTRAST MEDIUM; DIAGNOSTIC AGENT; PHOSPHOLIPID; SULFUR HEXAFLUORIDE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL EVALUATION; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DISEASE COURSE; ECHOGRAPHY; FEMALE; FOLLOW UP; HEMATOMA; HORMONAL THERAPY; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; PLEURA EFFUSION; PRIORITY JOURNAL; PROGNOSIS; RADIOFREQUENCY ABLATION; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR NECROSIS; TUMOR VOLUME; BREAST TUMOR; CATHETER ABLATION; ENDOSCOPIC ECHOGRAPHY; LIVER TUMOR; METASTASIS; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME;

AGED; BREAST NEOPLASMS; CATHETER ABLATION; CONTRAST MEDIA; DISEASE PROGRESSION; FEMALE; HUMANS; IOPAMIDOL; LIVER NEOPLASMS; MIDDLE AGED; PHOSPHOLIPIDS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SULFUR HEXAFLUORIDE; SURVIVAL RATE; TREATMENT OUTCOME; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 73949131091     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2533081968     Document Type: Article

References (54)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18:581-592.
3. Hoe AL, Royle GT, Taylor I. Breast liver metastases: incidence, diagnosis and outcome. J R Soc Med 1991;84:714-716.
4. Zinser JW, Hortobagyi GN, Buzdar AU, Smith TL, Fraschini G. Clinical course of breast cancer patients with liver metastases. J Clin Oncol 1987;5:773-782.
5. Atalay G, Biganzoli L, Renard F, et al. Clinical outcome of breast cancer patients with liver metastases alone in the anthracyclinetaxane era: a retrospective analysis of two prospective, randomised metastatic breast cancer trials. Eur J Cancer 2003;39:2439-2449.
6. Elias D, Lasser P, Spielmann M, et al. Surgical and chemotherapeutic treatment of hepatic metastases from carcinoma of the breast. Surg Gynecol Obstet 1991;172:461-464.
7. Stockler M, Wilcken NR, Ghersi D, Simes RJ. Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treat Rev 2000;26:151-168.
8. Miller KD, Sledge GW. The role of chemotherapy for metastatic breast cancer. Hematol Oncol Clin North Am 1999;13:415-434.
9. Er O, Frye DK, Kau SC, et al. Clinical course of breast cancer patients with metastases limited to the liver treated with chemotherapy. Cancer J 2008;14:62-68.
10. Pentheroudakis G, Fountzilas G, Bafaloukos D, et al. Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women. Breast Cancer Res Treat 2006;97:237-244.
11. Batist G, Harris L, Azarnia N, Lee LW, Daza-Ramirez P. Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis. Anticancer Drugs 2006;17:587-595.
12. Aloia TA, Vauthey J, Loyer EM, et al. Solitary colorectal liver metastasis: resection determines outcome. Arch Surg 2006;141:460-466.
13. Curley SA. Outcomes after surgical treatment of colorectal cancer liver metastases. Semin Oncol 2005;32(6 suppl 9):S109-S111.
14. Malafosse R, Penna C, Sa Cunha A, Nordlinger B. Surgical management of hepatic metastases from colorectal malignancies. Ann Oncol 2001;12:887-894.
15. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of indications for resection - registry of hepatic metastases. Surgery 1988;103:278-288.
16. Schneebaum S, Walker MJ, Young D, Farrar WB, Minton JP. The regional treatment of liver metastases from breast cancer. J Surg Oncol 1994;55:26-31.
17. Pocard M, Pouillart P, Asselain B, Falcou MC, Salmon RJ. Hepatic resection for breast cancer metastases: results and prognosis (65 cases). Ann Chir 2001;126:413-420.
18. Selzner M, Morse MA, Vredenburgh JJ, Meyers WC, Clavien PA. Liver metastases from breast cancer: long-term survival after curative resection. Surgery 2000;127:383-389.
19. Adam R, Aloia T, Krissat J, et al. Is liver resection justified for patients with hepatic metastases from breast cancer? Ann Surg 2006;244:897-907.
20. Gannon CJ, Curley SA. The role of focal liver ablation in the treatment of unresectable primary and secondary malignant liver tumors. Semin Radiat Oncol 2005;15:265-272.
21. Livraghi T, Meloni F, Di Stasi M, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology 2008;47:82-89.
22. Gillams AR. Image guided tumour ablation. Cancer Imaging 2005;5:103-109.
23. Lencioni R, Crocetti L, Cioni D, Della Pina C, Bartolozzi C. Percutaneous radiofrequency ablation of hepatic colorectal metastases: technique, indications, results, and new promises. Invest Radiol 2004;39:689-697.
24. Winter TC, Laeseke PF, Lee FT. Focal tumor ablation: a new era in cancer therapy. Ultrasound Q 2006;22:195-217.
25. Clark HP, Carson WF, Kavanagh PV, Ho CP, Shen P, Zagoria RJ. Staging and current treatment of hepatocellular carcinoma. RadioGraphics 2005;25(suppl 1):S3-S23.
26. Al-Asfoor A, Fedorowicz Z, Lodge M. Resection versus no intervention or other surgical interventions for colorectal cancer liver metastases. Cochrane Database Syst Rev 2008; Apr 16;(2):CD006039.
27. Garrean S, Hering J, Saied A, Helton WS, Espat NJ. Radiofrequency ablation of primary and metastatic liver tumors: a critical review of the literature. Am J Surg 2008;195:508-520.
28. Gazelle GS, Hunink MGM, Kuntz KM, et al. Cost-effectiveness of hepatic metastasectomy in patients with metastatic colorectal carcinoma: a state-transition Monte Carlo decision analysis. Ann Surg 2003;237:544-555.
29. Gazelle GS, McMahon PM, Beinfeld MT, Halpern EF, Weinstein MC. Metastatic colorectal carcinoma: cost-effectiveness of percutaneous radiofrequency ablation versus that of hepatic resection. Radiology 2004;233:729-739.
30. Livraghi T, Goldberg SN, Solbiati L, Meloni F, Ierace T, Gazelle GS. Percutaneous radiofrequency ablation of liver metastases from breast cancer: initial experience in 24 patients. Radiology 2001;220:145-149.
31. Mack MG, Straub R, Eichler K, Söllner O, Lehnert T, Vogl TJ. Breast cancer metastases in liver: laser-induced interstitial thermotherapy - local tumor control rate and survival data. Radiology 2004;233:400-409.
32. Lu MD, Yu XL, Li AH, et al. Comparison of contrast enhanced ultrasound and contrast enhanced CT or MRI in monitoring percutaneous thermal ablation procedure in patients with hepatocellular carcinoma: a multi-center study in China. Ultrasound Med Biol 2007;33:1736-1749.
33. Solbiati L, Ierace T, Tonolini M, Cova L. Guidance and monitoring of radiofrequency liver tumor ablation with contrast-enhanced ultrasound. Eur J Radiol 2004;51(suppl):S19-S23.
34. Kim CK, Choi D, Lim HK, et al. Therapeutic response assessment of percutaneous radiofrequency ablation for hepatocellular carcinoma: utility of contrast-enhanced agent detection imaging. Eur J Radiol 2005;56:66-73.
35. Meloni MF, Livraghi T, Filice C, Lazzaroni S, Calliada F, Perretti L. Radiofrequency ablation of liver tumors: the role of microbubble ultrasound contrast agents. Ultrasound Q 2006;22:41-47.
36. Poon RT. Is radiofrequency ablation the treatment of choice for patients with small hepatocellular carcinoma? Nat Clin Pract Gastroenterol Hepatol 2008;5:492-493.
37. Gillams AR, Lees WR. Radiofrequency ablation of colorectal liver metastases. Abdom Imaging 2005;30:419-426.
38. de Meijer VE, Ijzermans JN, Verhoef C. A place for radiofrequency ablation in the treatment of resectable colorectal liver metastases? Ann Surg Oncol 2008;15:2063.
39. Pereira PL. Actual role of radiofrequency ablation of liver metastases. Eur Radiol 2007;17:2062-2070.
40. Rossi S, Di Stasi M, Buscarini E, et al. Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer. AJR Am J Roentgenol 1996;167:759-768.
41. Solbiati L, Livraghi T, Goldberg SN, et al. Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology 2001;221:159-166.
42. Gunabushanam G, Sharma S, Thulkar S, et al. Radiofrequency ablation of liver metastases from breast cancer: results in 14 patients. J Vasc Interv Radiol 2007;18:67-72.
43. Sofocleous CT, Nascimento RG, Gonen M, et al. Radiofrequency ablation in the management of liver metastases from breast cancer. AJR Am J Roentgenol 2007;189:883-889.
44. Jakobs TF, Hoffmann RT, Schrader A, et al. CT-guided radiofrequency ablation in patients with hepatic metastases from breast cancer. Cardiovasc Intervent Radiol 2009;32:38-46.
45. Abe H, Kurumi Y, Naka S, et al. Open-configuration MR-guided microwave thermocoagulation therapy for metastatic liver tumors from breast cancer. Breast Cancer 2005;12:26-31.
46. Vlastos G, Smith DL, Singletary SE, et al. Long-term survival after an aggressive surgical approach in patients with breast cancer hepatic metastases. Ann Surg Oncol 2004;11:869-874.
47. Raab R, Nussbaum KT, Behrend M, Weimann A. Liver metastases of breast cancer: results of liver resection. Anticancer Res 1998;18:2231-2233.
48. Yoshimoto M, Tada T, Saito M, et al. Surgical treatment of hepatic metastases from breast cancer. Breast Cancer Res Treat 2000;59:177-184.
49. Kondo S, Katoh H, Omi M, et al. Hepatectomy for metastases from breast cancer offers the survival benefit similar to that in hepatic metastases from colorectal cancer. Hepatogastroenterology 2000;47:1501-1503.
50. Caralt M, Bilbao I, Cortés J, et al. Hepatic resection for liver metastases as part of the "oncosurgical" treatment of metastatic breast cancer. Ann Surg Oncol 2008;15:2804-2810.
51. d'Annibale M, Piovanello P, Cerasoli V, Campioni N. Liver metastases from breast cancer: the role of surgical treatment. Hepatogastroenterology 2005;52:1858-1862.
52. Lubrano J, Roman H, Tarrab S, Resch B, Marpeau L, Scotté M. Liver resection for breast cancer metastasis: does it improve survival? Surg Today 2008;38:293-299.
53. Lambert LA, Colacchio TA, Barth RJ. Interval hepatic resection of colorectal metastases improves patient selection. Arch Surg 2000;135:473-479.
54. Livraghi T, Solbiati L, Meloni F, Ierace T, Goldberg SN, Gazelle GS. Percutaneous radiofrequency ablation of liver metastases in potential candidates for resection: the "test-of-time approach". Cancer 2003;97:3027-3035.